{
  "url": "https://openlegislation.uk/eu-regulation-2017-776/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2017-776/annex.json",
  "legislation": "eur/2017/776",
  "legislation_title": "Commission Regulation (EU) 2017/776 of 4 May 2017 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2017-776",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "Annex VI to Regulation (EC) No 1272/2008 is amended as follows:\n(1) the introductory paragraphs are replaced by the following:\n‘Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3.\nPart 2 of this Annex lays down general principles for preparing dossiers to propose and justify harmonised classification and labelling of substances at Union level.\nPart 3 of this Annex lists hazardous substances for which harmonised classification and labelling have been established at Union level. In Table 3 the classification and labelling are based on the criteria in Annex I to this Regulation.’;\n(2) Part 1 is amended as follows:\n(a) the title of Section 1.1.2 is replaced by the following:\n‘1.1.2.\nInformation related to the classification and labelling of each entry in Table 3 ’;\n(b) Section 1.1.2.3 is replaced by the following:\n‘1.1.2.3.\nSpecific concentration limits, M-factors and Acute Toxicity Estimates (ATE)\nSpecific concentration limits (SCL), where different from the generic concentration limits given in Annex I for a certain category, are given in a separate column together with the classification concerned using the same codes as under 1.1.2.1.1. Also harmonised ATEs are listed in the same column of table 3. The SCLs and harmonised ATEs must be used by the manufacturer, importer or downstream user for the classification of a mixture containing this substance. When applying an ATE, the additivity formula as described in 3.1.3.6 of Annex I shall be used. Where no specific concentration limits are given in this Annex for a certain category, the generic concentration limits given in Annex I must be applied for the classification of substances containing impurities, additives or individual constituents or for mixtures. If harmonised ATE values are missing for acute toxicity the correct value has to be established by using the available data.\nUnless otherwise shown, the concentration limits are a percentage by weight of the substance calculated with reference to the total weight of the mixture.\nIn case an M-factor has been harmonised for substances classified as hazardous to the aquatic environment in the categories Aquatic Acute 1 or Aquatic Chronic 1, that M-factor is given in Table 3 in the same column as the specific concentration limits. In case an M-factor for Aquatic Acute 1 and an M-factor for Aquatic Chronic 1 have been harmonised, each M-factor shall be listed in the same line as its corresponding differentiation. Where a single M-factor is given in Table 3 and the substance is classified as Aquatic Acute 1 and Aquatic Chronic 1, that M-factor shall be used by the manufacturer, importer or downstream user for the classification of a mixture containing this substance for acute and long-term aquatic hazards using the summation method. Where no M-factor is given in Table 3, M-factor(s) based on available data for the substance shall be set by the manufacturer, importer or downstream user. For the setting and use of M-factors, see Section 4.1.3.5.5.5 of Annex I.’;\n(c) Section 1.1.3.1 is amended as follows:\n(i) Note E is deleted;\n(ii) Note K is replaced by the following:\n‘ Note K:\nThe classification as a carcinogen or mutagen need not apply if it can be shown that the substance contains less than 0,1 % w/w 1,3-butadiene (Einecs No 203-450-8). If the substance is not classified as a carcinogen or mutagen, at least the precautionary statements (P102-)P210-P403 should apply. This note applies only to certain complex oil-derived substances in Part 3.’;\n(iii) Note P is replaced by the following:\n‘ Note P:\nThe classification as a carcinogen or mutagen need not apply if it can be shown that the substance contains less than 0,1 % w/w benzene (Einecs No 200-753-7).\nWhen the substance is not classified as a carcinogen at least the precautionary statements (P102-)P260-P262-P301 + P310-P331 shall apply.\nThis note applies only to certain complex oil-derived substances in Part 3.’;\n(iv) Note S is replaced by the following:\n‘ Note S:\nThis substance may not require a label according to Article 17 (see Section 1.3 of Annex I) (Table 3).’;\n(v) in Note U, the title is replaced by the following:\n‘ Note U (Table 3): ’;\n(d) Section 1.1.3.2 is amended as follows:\n(i) Note 1 is replaced by the following:\n‘ Note 1:\nThe concentration stated or, in the absence of such concentrations, the generic concentrations set out in this Regulation are the percentages by weight of the metallic element calculated with reference to the total weight of the mixture.’;\n(ii) Note 8 is added as follows:\n‘ Note 8:\nThe classification as a carcinogen need not apply if it can be shown that the maximum theoretical concentration of releasable formaldehyde, irrespective of the source, in the mixture as placed on the market is less than 0,1 %.’;\n(iii) Note 9 is added as follows:\n‘ Note 9:\nThe classification as a mutagen need not apply if it can be shown that the maximum theoretical concentration of releasable formaldehyde, irrespective of the source, in the mixture as placed on the market is less than 1 %.’;\n(e) Section 1.1.4 is deleted;\n(f) The Title of Section 1.2 is replaced by the following:\n‘1.2.\nClassifications and hazard statements in Table 3 arising from translation of classifications listed in Annex I to directive 67/548/EEC ’;\n(g) Section 1.2.1 is replaced by the following:\n‘1.2.1.\nMinimum classification\nFor certain hazard classes, including acute toxicity and STOT repeated exposure, the classification according to the criteria in Directive 67/548/EEC does not correspond directly to the classification in a hazard class and category under this Regulation. In these cases the classification in this Annex shall be considered as a minimum classification. This classification shall be applied if none of the following conditions are fulfilled:\nthe manufacturer or importer has access to data or other information, as specified in Part 1 of Annex I, that lead to classification in a more severe category compared to the minimum classification. Classification in the more severe category must then be applied,\nthe minimum classification can be further refined based on the translation table in Annex VII when the physical state of the substance used in the acute inhalation toxicity test is known to the manufacturer or importer. The classification as obtained from Annex VII shall then substitute the minimum classification indicated in this Annex if it differs from it.\nMinimum classification for a category is indicated by the reference * in the column “Classification” in Table 3.\nThe reference * can also be found in the column “Specific Conc. Limits and M-factors and Acute Toxicity Estimates (ATE)” where it indicates that the entry concerned had specific concentration limits under Directive 67/548/EEC for acute toxicity. These concentration limits cannot be “translated” into concentration limits under this Regulation, especially when a minimum classification is given. However, when the reference * is shown, the classification for acute toxicity for this entry may be of special concern.’;\n(h) Section 1.2.2 is replaced by the following:\n‘1.2.2.\nRoute of exposure cannot be excluded\nFor certain hazard classes, e.g. STOT, the route of exposure should be indicated in the hazard statement only if it is conclusively proven that no other route of exposure can cause the hazard in accordance to the criteria in Annex I. Under Directive 67/548/EEC the route of exposure was indicated for classifications with R48 when there was data justifying the classification for this route of exposure. The classification under 67/548/EEC indicating the route of exposure has been translated into the corresponding class and category according to this Regulation, but with a general hazard statement not specifying the route of exposure as the necessary information is not available.\nThese hazard statements are indicated by the reference ** in Table 3.’;\n(i) Section 1.2.3 is replaced by the following:\n‘1.2.3.\nHazard statements for reproductive toxicity\nHazard statements H360 and H361 indicate a general concern for effects on fertility and/or development: “May damage/Suspected of damaging fertility or the unborn child”. According to the criteria, the general hazard statement can be replaced by the hazard statement indicating the specific effect of concern in accordance with Section 1.1.2.1.2. When the other differentiation is not mentioned, this is due to evidence proving no such effect, inconclusive data or no data and the obligations in Article 4(3) shall apply for that differentiation.\nIn order not to lose information from the harmonised classifications for fertility and developmental effects under Directive 67/548/EEC, the classifications have been translated only for those effects classified under that Directive.\nThese hazard statements are indicated by the reference *** in Table 3.’;\n(j) Section 1.2.4 is replaced by the following:\n‘1.2.4.\nCorrect classification for physical hazards could not be established\nFor some entries the correct classification for physical hazards could not be established because sufficient data are not available for the application of the classification criteria in this Regulation. The entry might be assigned to a different (also higher) category or even another hazard class than indicated. The correct classification shall be confirmed by testing.\nThe entries with physical hazards that need to be confirmed by testing are indicated by the reference **** in Table 3.’;\n(3) Part 3 is amended as follows:\n(a) the header of Part 3 is replaced by the following:\n‘3.\nPART 3: HARMONISED CLASSIFICATION AND LABELLING TABLE’;\n(b) the introductory paragraphs are deleted;\n(c) the title of Table 3.1 is replaced by the following:\n‘ Table 3\nList of harmonised classification and labelling of hazardous substances ’;\n(d) Table 3 is amended as follows:\n(i) the title of the penultimate column is replaced by ‘Specific Conc. Limits, M-factors and ATE’;\n(ii) the entries corresponding to index numbers 006-046-00-8, 604-057-00-8, 605-023-00-5, 606-041-00-6, 607-123-00-4, 608-055-00-8, 612-150-00-X, 613-318-00-5, 614-001-00-4, 615-013-00-2, 616-006-00-7, 616-094-00-7 and 650-032-00-X are replaced by the following corresponding entries:\nConverted acute toxicity point estimate according to Table 3.1.2 of Annex I.\nIndex No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors and ATE\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘006-046-00-8\nbendiocarb (ISO);\n2,2-dimethyl-1,3-benzodioxol-4-yl N-methylcarbamate;\n2,2-dimethyl-1,3-benzodioxol-4-yl methylcarbamate\n245-216-8\n22781-23-3\nAcute Tox. 3\nAcute Tox. 3\nAcute Tox. 2\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH311\nH300\nH410\nM = 10\nM = 100’\n‘604-057-00-8\nreaction mass of: isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-tetracosylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n = 5 or 6\n401-680-5\n—\nAquatic Chronic 4\nH413\nH413’\n‘605-023-00-5\n5-chloro-2-(4-chlorophenoxy)phenol;\n[DCPP]\n429-290-0\n3380-30-1\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\nM = 10\nM = 10’\n‘606-041-00-6\n2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one\n400-600-6\n71868-10-5\nRepr. 1B\nAcute Tox. 4 *\nAquatic Chronic 2\nH360FD\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH360FD\nH302\nH411’\n‘607-123-00-4\n2,3-epoxypropyl methacrylate;\nglycidyl methacrylate\n203-441-9\n106-91-2\nCarc. 1B\nMuta. 2\nRepr. 1B\nAcute Tox. 3\nAcute Tox. 4\nSTOT SE 3\nSTOT RE 1\nEye Dam. 1\nSkin Corr. 1C\nSkin Sens. 1\nH350\nH341\nH360F\nH311\nH302\nH335\nH372 (respiratory tract) (inhalation)\nH318\nH314\nH317\nGHS08\nGHS06\nGHS05\nDgr\nH350\nH341\nH360F\nH311\nH302\nH335\nH372 (respiratory tract) (inhalation)\nH314\nH317\nD’\n‘608-055-00-8\nfipronil (ISO);\n(±)-5-amino-1-(2,6-dichloro-α,α,α-trifluoro-para-tolyl)-4-trifluoromethylsulfinyl-pyrazole-3-carbonitrile\n424-610-5\n120068-37-3\nAcute Tox. 3*\nAcute Tox. 3*\nAcute Tox. 3*\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH311\nH331\nH372*\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH311\nH331\nH372*\nH410\nM = 1 000\nM = 10 000’\n‘612-150-00-X\nspiroxamine (ISO);\n8-tert-butyl-1,4-dioxaspiro[4.5]decan-2-ylmethyl(ethyl)(propyl)amine\n—\n118134-30-8\nRepr. 2\nAcute Tox. 4\nAcute Tox. 4\nAcute Tox. 4\nSTOT RE 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH332\nH312\nH302\nH373 (eye)\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d\nH332\nH312\nH302\nH373 (eye)\nH315\nH317\nH410\nM = 100\nM = 100’\n‘613-318-00-5\nfenpyrazamine (ISO);\nS-allyl 5-amino-2,3-dihydro-2-isopropyl-3-oxo-4-(o-tolyl)pyrazole-1-carbothioate;\nS-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydropyrazole-1-carbothioate\n—\n473798-59-3\nAquatic Acute 1 Aquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 10\nM = 1’\n‘614-001-00-4\nnicotine (ISO);\n3-[(2S)-1-methylpyrrolidin-2-yl]pyridine\n200-193-3\n54-11-5\nAcute Tox. 2\nAcute Tox. 2\nAcute Tox. 2\nAquatic Chronic 2\nH330\nH310\nH300\nH411\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH411\ninhalation:\nATE = 0.19 mg/L (dusts or mists)\ndermal:\nATE = 70 mg/kg\noral:\nATE = 5 mg/kg’\n‘615-013-00-2\ncyanamide;\ncarbamonitril\n206-992-3\n420-04-2\nCarc. 2\nRepr. 2\nAcute Tox. 3\nAcute Tox. 3\nSTOT RE 2\nSkin Corr. 1\nSkin Sens. 1\nEye Dam. 1\nAquatic Chronic 3\nH351\nH361fd\nH311\nH301\nH373 (thyroid)\nH314\nH317\nH318\nH412\nGHS08\nGHS06\nGHS05\nDgr\nH351\nH361fd\nH311\nH301\nH373 (thyroid)\nH314\nH317\nH412’\n‘616-006-00-7\ndichlofluanid (ISO);\nN-[(dichlorofluoromethyl)thio]-N′,N′-dimethyl-N-phenylsulfamide\n214-118-7\n1085-98-9\nAcute Tox. 4\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH332\nH319\nH317\nH400\nGHS07\nGHS09\nWng\nH332\nH319\nH317\nH400\nM = 10’\n‘616-094-00-7\n3,3′-dicyclohexyl-1,1′-methylenebis(4,1-phenylene)diurea\n406-370-3\n58890-25-8\nAquatic Chronic 4\nH413\nH413’\n‘650-032-00-X\ncyproconazole (ISO); (2RS,3RS;2RS,3SR)-2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol\n—\n94361-06-5\nRepr. 1B\nAcute Tox. 3\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH301\nH373 (liver)\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH360D\nH301\nH373 (liver)\nH410\nM = 10\nM = 1’\n(iii) the following entries are inserted in accordance with the order of the entries set out in Table 3:\nIndex No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors and ATE\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘047-003-00-3\nsilver zinc zeolite (Zeolite, LTA framework type, surface-modified with silver and zinc ions)\n[This entry covers LTA (Linde Type A) framework type zeolite which has been surface-modified with both silver and zinc ions at contents Ag+ 0,5 %-6 %, Zn2 + 5 %-16 %, and potentially with phosphorus, NH4+, Mg2+ and/or Ca2+ each at level < 3 %]\n—\n130328-20-0\nRepr. 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH315\nH318\nH400\nH410\nGHS08\nGHS05\nGHS09\nDgr\nH361d\nH315\nH318\nH410\nM = 100\nM = 100’\n‘048-012-00-5\ncadmium carbonate\n208-168-9\n513-78-0\nCarc. 1B\nMuta. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH340\nH332\nH312\nH302\nH372 (kidney, bone)\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH340\nH332\nH312\nH302\nH372 (kidney, bone)\nH410\nA1’\n‘048-013-00-0\ncadmium hydroxide; cadmium dihydroxide\n244-168-5\n21041-95-2\nCarc. 1B\nMuta. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH340\nH332\nH312\nH302\nH372 (kidney, bone)\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH340\nH332\nH312\nH302\nH372 (kidney, bone)\nH410\nA1’\n‘048-014-00-6\ncadmium nitrate;\ncadmium dinitrate\n233-710-6\n10325-94-7\nCarc. 1B\nMuta. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH340\nH332\nH312\nH302\nH372 (kidney, bone)\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH340\nH332\nH312\nH302\nH372 (kidney, bone)\nH410\nCarc. 1B; H350:\nC ≥ 0,01 %\nA1’\n‘050-030-00-3\ndibutyltin dilaurate; dibutyl[bis(dodecanoyloxy)]stannane\n201-039-8\n77-58-7\nMuta. 2\nRepr. 1B\nSTOT RE 1\nH341\nH360FD\nH372 (immune system)\nGHS08\nDgr\nH341\nH360FD\nH372 (immune system)’\n‘603-235-00-2\nlinalool; 3,7-dimethyl-1,6-octadien-3-ol; dl-linalool; [1]\ncoriandrol; (S)-3,7-dimethyl-1,6-octadien-3-ol; d-linalool; [2]\nlicareol; (R)-3,7-dimethyl-1,6-octadien-3-ol; l-linalool [3]\n201-134-4 [1]\n204-810-7 [2]\n204-811-2 [3]\n78-70-6 [1]\n126-90-9 [2]\n126-91-0 [3]\nSkin Sens. 1B\nH317\nGHS07\nWng\nH317’\n‘604-093-00-4\nclorofene;\nchlorophene;\n2-benzyl-4-chlorophenol\n204-385-8\n120-32-1\nCarc. 2\nRepr. 2\nAcute Tox. 4\nSkin Irrit. 2\nSkin Sens. 1\nEye Dam. 1\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361f\nH332\nH315\nH317\nH318\nH373 (kidney)\nH400\nH410\nGHS08\nGHS05\nGHS07\nGHS09\nDgr\nH351\nH361f\nH332\nH315\nH317\nH318\nH373 (kidney)\nH410\nM = 1\nM = 100’\n‘606-150-00-9\nclethodim (ISO); (5RS)-2-{(1EZ)-1-[(2E)-3-chloroallyloxyimino]propyl}-5-[(2RS)-2-(ethylthio)propyl]-3-hydroxycyclohex-2-en-1-one\n—\n99129-21-2\nAcute Tox. 4\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\nEUH066’\n‘606-151-00-4\nanthraquinone\n201-549-0\n84-65-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350’\n‘607-720-00-X\nnonadecafluorodecanoic acid; [1]\nammonium nonadecafluorodecanoate; [2]\nsodium nonadecafluorodecanoate [3]\n206-400-3 [1] 221-470-5 [2]\n[3]\n335-76-2 [1] 3108-42-7 [2]\n3830-45-3 [3]\nCarc. 2\nRepr. 1B\nLact.\nH351\nH360Df\nH362\nGHS08\nDgr\nH351\nH360Df\nH362’\n‘607-721-00-5\nN,N′-methylenedimorpholine;\nN,N′-methylenebismorpholine;\n[formaldehyde released from N,N′-methylenebismorpholine];\n[MBM]\n227-062-3\n5625-90-1\nCarc. 1B\nMuta. 2\nAcute Tox. 4\nAcute Tox. 4\nAcute Tox. 4\nSTOT RE 2\nSkin Corr. 1B\nSkin Sens. 1\nEye Dam. 1\nH350\nH341\nH332\nH312\nH302\nH373 (gastrointestinal tract, respiratory tract)\nH314\nH317\nH318\nGHS08\nGHS07\nGHS05\nDgr\nH350\nH341\nH332\nH312\nH302\nH373 (gastrointestinal tract, respiratory tract)\nH314\nH317\nEUH071\n8\n9’\n‘607-722-00-0\n2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (Z)-(1R,3R)-3-(2-cyanoprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate;\nepsilon-momfluorothrin\n—\n1065124-65-3\nAcute Tox. 4\nSTOT SE 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH371 (nervous system)\nH400\nH410\nGHS07\nGHS08\nGHS09\nWng\nH302\nH371 (nervous system)\nH410\nM = 100\nM = 100’\n‘607-723-00-6\ntefluthrin (ISO);\n2,3,5,6-tetrafluoro-4-methylbenzyl (1RS,3RS)-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropanecarboxylate\n—\n79538-32-2\nAcute Tox. 1\nAcute Tox. 2\nAcute Tox. 2\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH300\nH400\nH410\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH410\nM = 10 000\nM = 10 000’\n‘612-290-00-1\nreaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 3:2);\n[formaldehyde released from 3,3′-methylenebis[5-methyloxazolidine];\nformaldehyde released from oxazolidin];\n[MBO]\n—\n—\nCarc. 1B\nMuta. 2\nAcute Tox. 4\nAcute Tox. 3\nAcute Tox. 4\nSTOT RE 2\nSkin Corr. 1B\nEye Dam. 1\nSkin Sens. 1A\nAquatic Chronic 2\nH350\nH341\nH332\nH311\nH302\nH373 (gastrointestinal tract, respiratory tract)\nH314\nH318\nH317\nH411\nGHS08\nGHS06\nGHS05\nGHS09\nDgr\nH350\nH341\nH332\nH311\nH302\nH373 (gastrointestinal tract, respiratory tract)\nH314\nH317\nH411\nEUH071\n8\n9’\n‘612-291-00-7\nreaction products of paraformaldehyde with 2-hydroxypropylamine (ratio 1:1);\n[formaldehyde released from α,α,α-trimethyl-1,3,5-triazine-1,3,5(2H,4H,6H)-triethanol];\n[HPT]\n—\n—\nCarc. 1B\nMuta. 2\nAcute Tox. 4\nAcute Tox. 4\nSTOT RE 2\nSkin Corr. 1C\nEye Dam. 1\nSkin Sens. 1A\nAquatic Chronic 2\nH350\nH341\nH332\nH302\nH373 (gastrointestinal tract, respiratory tract)\nH314\nH318\nH317\nH411\nGHS08\nGHS07\nGHS05\nGHS09\nDgr\nH350\nH341\nH332\nH302\nH373 (gastrointestinal tract, respiratory tract)\nH314\nH317\nH411\nEUH071\n8\n9’\n‘612-292-00-2\nmethylhydrazine\n200-471-4\n60-34-4\nCarc. 1B\nH350\nGHS08\nDgr\nH350’\n‘613-321-00-1\n(RS)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;\nmedetomidine\n—\n86347-14-0\nAcute Tox. 2\nAcute Tox. 2\nSTOT SE 3\nSTOT SE 1\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH300\nH336\nH370 (eye)\nH372\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH330\nH300\nH336\nH370 (eye)\nH372\nH410\nM = 1\nM = 100’\n‘613-322-00-7\ntriadimenol (ISO); (1RS,2RS;1RS,2SR)-1-(4-chlorophenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol;\nα-tert-butyl-β-(4-chlorophenoxy)-1H-1,2,4-triazole-1-ethanol\n259-537-6\n55219-65-3\nRepr. 1B\nLact.\nAcute Tox. 4\nAquatic Chronic 2\nH360\nH362\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH360\nH362\nH302\nH411’\n‘613-323-00-2\nterbuthylazine (ISO);\nN-tert-butyl-6-chloro-N′-ethyl-1,3,5-triazine-2,4-diamine\n227-637-9\n5915-41-3\nAcute Tox. 4\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373\nH400\nH410\nGHS07\nGHS08\nGHS09\nWng\nH302\nH373\nH410\nM = 10\nM = 10’\n‘613-324-00-8\nquinolin-8-ol;\n8-hydroxyquinoline\n205-711-1\n148-24-3\nRepr. 1B\nAcute Tox. 3\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH301\nH318\nH317\nH400\nH410\nGHS08\nGHS06\nGHS05\nGHS09\nDgr\nH360D\nH301\nH318\nH317\nH410\nM = 1\nM = 1’\n‘613-325-00-3\nthiacloprid (ISO);\n(Z)-3-(6-chloro-3-pyridylmethyl)-1,3-thiazolidin-2-ylidenecyanamide;\n{(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide\n—\n111988-49-9\nCarc. 2\nRepr. 1B\nAcute Tox. 4\nAcute Tox. 3\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH360FD\nH332\nH301\nH336\nH400\nH410\nGHS08 GHS06\nGHS09\nDgr\nH351\nH360FD\nH332\nH301\nH336\nH410\nM = 100\nM = 100’\n‘616-221-00-6\nhexaflumuron (ISO);\n1-(3,5-dichloro-4-(1,1,2,2-tetrafluoroethoxy)phenyl)-3-(2,6-difluorobenzoyl)urea\n401-400-1\n86479-06-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1 000\nM = 10 000’\n‘616-222-00-1\npenthiopyrad (ISO);\n(RS)-N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxamide\n—\n183675-82-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1\nM = 1’\n‘616-223-00-7\ncarbetamide (ISO);\n(R)-1-(ethylcarbamoyl)ethyl carbanilate; (2R)-1-(ethylamino)-1-oxopropan-2-yl phenylcarbamate\n240-286-6\n16118-49-3\nCarc. 2\nRepr. 1B\nAcute Tox. 4\nAquatic Chronic 2\nH351\nH360D\nH302\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360D\nH302\nH411’",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "Converted acute toxicity point estimate according to Table 3.1.2 of Annex I."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2017/776/annex",
    "retrieved_at": "2026-11-01T14:44:56.942116+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}